Search

Search Constraints

You searched for: Author/Creator Volteau, Magali

Search Results

3. AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Issue 1 (2nd November 2022)

4. Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines. (19th March 2021)

5. Dose‐Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. Issue 1 (19th June 2017)

6. J07 What can we learn from a phase ii study with BN82451B in hd beyond safety and tolerability – clinical versus objective motor measures. (September 2018)

7. Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment. Issue 11 (7th November 2022)

8. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial. (14th February 2017)

9. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines. (20th March 2019)

10. Long-term efficacy and safety of abobotulinumtoxinA solution for the treatment of moderate-to-severe glabellar lines: A Phase III, double-blind, placebo-controlled and open-label repeat injection study. (January 2021)